SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001387131-21-006257
Filing Date
2021-06-01
Accepted
2021-06-01 16:35:47
Documents
13
Period of Report
2021-05-25
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT admp-8k_052521.htm   iXBRL 8-K 24900
2 PRESS RELEASE ex99-1.htm EX-99.1 7207
  Complete submission text file 0001387131-21-006257.txt   207952

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE admp-20210525.xsd EX-101.SCH 2999
4 XBRL LABEL FILE admp-20210525_lab.xml EX-101.LAB 34238
5 XBRL PRESENTATION FILE admp-20210525_pre.xml EX-101.PRE 22341
6 EXTRACTED XBRL INSTANCE DOCUMENT admp-8k_052521_htm.xml XML 3593
Mailing Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 997-2400
Adamis Pharmaceuticals Corp (Filer) CIK: 0000887247 (see all company filings)

IRS No.: 820429727 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36242 | Film No.: 21985829
SIC: 2834 Pharmaceutical Preparations